Royce & Associates LP cut its holdings in shares of Uniqure NV (NASDAQ:QURE) by 20.0% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 100,000 shares of the biotechnology company’s stock after selling 25,000 shares during the quarter. Royce & Associates LP’s holdings in Uniqure were worth $3,780,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Quantbot Technologies LP lifted its position in Uniqure by 3,972.6% during the first quarter. Quantbot Technologies LP now owns 5,498 shares of the biotechnology company’s stock worth $129,000 after buying an additional 5,363 shares during the period. Financial Gravity Wealth Inc. purchased a new position in Uniqure during the first quarter worth about $177,000. Ladenburg Thalmann Financial Services Inc. lifted its position in Uniqure by 276.5% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,400 shares of the biotechnology company’s stock worth $150,000 after buying an additional 4,700 shares during the period. Atria Investments LLC purchased a new position in Uniqure during the second quarter worth about $247,000. Finally, Trexquant Investment LP purchased a new position in Uniqure during the second quarter worth about $272,000. Hedge funds and other institutional investors own 59.33% of the company’s stock.
Several research firms recently weighed in on QURE. Zacks Investment Research upgraded Uniqure from a “hold” rating to a “buy” rating and set a $44.00 target price on the stock in a research report on Wednesday, July 4th. HC Wainwright set a $42.00 target price on Uniqure and gave the stock a “buy” rating in a research report on Thursday, August 23rd. Cantor Fitzgerald set a $58.00 price objective on Uniqure and gave the stock a “buy” rating in a report on Thursday, August 23rd. Cowen restated a “buy” rating on shares of Uniqure in a report on Monday, August 13th. Finally, B. Riley started coverage on Uniqure in a report on Wednesday, June 27th. They issued a “buy” rating and a $50.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $44.89.
Uniqure stock opened at $43.08 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.36 and a quick ratio of 8.36. Uniqure NV has a 12 month low of $7.52 and a 12 month high of $43.20.
Uniqure (NASDAQ:QURE) last released its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.04. The company had revenue of $3.05 million for the quarter, compared to the consensus estimate of $3.37 million. Uniqure had a negative return on equity of 72.12% and a negative net margin of 677.98%. equities analysts predict that Uniqure NV will post -2.44 earnings per share for the current year.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Featured Article: Book Value Of Equity Per Share – BVPS Explained
Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Uniqure NV (NASDAQ:QURE).
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.